Use of hemoglobin A1c to identify dysglycemia in cystic fibrosis
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cystic fibrosis (CF) leads to pancreatic endocrine dysfunction with progressive glycemic disturbance. Approximately 30%-50% of people with CF eventually develop CF-related diabetes (CFRD). Pre-CFRD states progress from indeterminant glycemia (INDET) to impaired fasting glucose (IFG) or impaired glucose tolerance (IGT). Screening guidelines recommend inconvenient annual 2-hour oral glucose tolerance tests (OGTTs), beginning at age 10 years. More efficient methods, such as hemoglobin A1C (HbA1c), have been evaluated, but only limited, relatively small studies have evaluated the association between HbA1c and pre-CFRD dysglycemic states. OBJECTIVE: To determine whether HbA1c is an appropriate screening tool for identifying patients with pre-CFRD dysglycemia to minimize the burden of annual OGTTs. METHODS: This retrospective review evaluated medical records data of all University of Massachusetts Memorial Health System CF patients with an HbA1c result within 90 days of an OGTT between 1997 and 2019. Exclusion criteria were uncertain CF diagnosis, other forms of diabetes, or incomplete OGTT. In total, 56 patients were included and categorized according to OGTT results (American Diabetes Association criteria): normal glucose tolerance, INDET, IFG, or IGT. Associations were evaluated between HbA1c and OGTT results and between HbA1c and pre-CFRD dysglycemic states. RESULTS: Mean HbA1c was not significantly different between patients with normal glucose tolerance and those in the INDET (p = 0.987), IFG (p = 0.690), and IGT (p = 0.874) groups. Analysis of variance confirmed the lack of association between HbA1c and glycemia, as mean HbA1c was not significantly different amongst the four categories (p = 0.250). CONCLUSION: There is increasing awareness of the impact of pre-CFRD states, including reduced pulmonary function and nutritional status. Unfortunately, our results do not support using HbA1c as a screening tool for pre-CFRD dysglycemia, specifically INDET, IFG, and IGT. Further studies are warranted to evaluate more efficient screening methods to reduce the burden of annual OGTTs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A1C is not recommended for screening due to low sensitivity; however, a value of $6.5% ($48 mmol/mol) is consistent with a diagnosis of CFRD and reduces patient screening burden (129-131).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [131]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A1C is not recommendedfor screening due to low sensitivity; however, a value $ 6.5% ( $ 48 mmol/mol) is consistent with a diagnosis of CFRD and reduces patient screening burden (127 -129).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [129]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A1C is not recommendedfor screening due to low sensitivity; however, a value $ 6.5% ( $ 48 mmol/mol) is consistent with a diagnosis of CFRD and reduces patient screening burden (127 -129).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [129]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Care Guidelines for Cystic Fibrosis–Related Diabetes
Moran, A., Brunzell, C., Cohen, R. C., Katz, M., Marshall, B. C., Onady, G., Robinson, K. A., Sabadosa, K. A., Stecenko, A., Slovis, B., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1768 · Cited by 726 · cited 4×
“Studies thus far have shown poor correlation between HbA1c and CFRD [2, 9, 10, 16, 17].”
BackgroundInfluentialCystic Fibrosis–Related Diabetes: Current Trends in Prevalence, Incidence, and Mortality
Moran, A., Dunitz, J., Nathan, B., Saeed, A., Holme, B., & Thomas, W. (2009) · Diabetes Care · doi:10.2337/dc09-0586 · Cited by 648 · cited 1×
“Approximately 40%–50% of people with CF will eventually develop CF-related diabetes (CFRD), with 20% diagnosed in adolescence [3].”
BackgroundMILLA, C. E., WARWICK, W. J., & MORAN, A. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.3.9904075 · Cited by 367
Lanng, S., Thorsteinsson, B., Nerup, J., & Koch, C. (1992) · European Journal of Pediatrics · doi:10.1007/bf01957574 · Cited by 267 · cited 2×
“A retrospective study by Lanng et al, evaluating 38 children and adults with CFRD, reported a gradual decline in BMI and pulmonary function up to 4 years before the diagnosis of CFRD [7].”
BackgroundMethodEarly Glucose Abnormalities in Cystic Fibrosis Are Preceded by Poor Weight Gain
Hameed, S., Morton, J. R., Jaffé, A., Field, P. I., Belessis, Y., Yoong, T., Katz, T., & Verge, C. F. (2010) · Diabetes Care · doi:10.2337/dc09-1492 · Cited by 173 · cited 1×
“reported that CFRD is a late event and that preceding glucose abnormalities were associated with a decline in lung function and body mass index (BMI) during the previous year [6].”
BackgroundGlucose Tolerance and Insulin Secretion, Morbidity, and Death in Patients with Cystic Fibrosis
Bismuth, É., Laborde, K., Taupin, P., Velho, G., Ribault, V., Jennane, F., Grasset, E., Sermet‐Gaudelus, I., Jacques de, B. L. I. C., Lenoir, G., et al. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2007.09.025 · Cited by 147 · cited 3×
“Studies thus far have shown poor correlation between HbA1c and CFRD [2, 9, 10, 16, 17].”
BackgroundBrodsky, J., Dougherty, S., Makani, R., Rubenstein, R. C., & Kelly, A. (2011) · Diabetes Care · doi:10.2337/dc10-1604 · Cited by 141 · cited 2×
“Because of early loss of the first phase insulin response, the OGTT of CF patients without CFRD often reveals major abnormalities in early insulin secretion [1, 18, 19].”
BackgroundCystic Fibrosis-Related Diabetes
Kayani, K., Mohammed, R., & Mohiaddin, H. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00020 · Cited by 128
Mechanisms of insulin resistance in cystic fibrosis
Hardin, D. S., Leblanc, A., Marshall, G. D., & Seilheimer, D. K. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.5.e1022 · Cited by 123 · cited 1×
“However, various clinical conditions may promote insulin resistance in CFRD, similar to type II diabetes [4, 5].”
BackgroundOral glucose tolerance testing in children with cystic fibrosis
Ode, K. L., Frohnert, B., Laguna, T., Phillips, J., Holme, B., Regelmann, W., Thomas, W., & Moran, A. (2010) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2009.00632.x · Cited by 122 · cited 2×
“This is followed by continued decline in insulin secretion, leading to the eventual diagnoses of indeterminant glycemia (INDET), impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) [1, 8, 12, 13].”
BackgroundMozzillo, E., Franzese, A., Valerio, G., Sepe, A., De Simone, I., Mazzarella, G., Ferri, P., & Raia, V. (2009) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00451.x · Cited by 108 · cited 1×
“Some studies have suggested that insulin treatment may be beneficial in dysglycemic states [21, 22].”
BackgroundLanng, S., Thorsteinsson, B., Røder, M. E., Ørskov, C., Holst, J. J., Nerup, J., & Koch, C. (1993) · Acta Endocrinologica · doi:10.1530/acta.0.1280207 · Cited by 107 · cited 1×
“Because of early loss of the first phase insulin response, the OGTT of CF patients without CFRD often reveals major abnormalities in early insulin secretion [1, 18, 19].”
BackgroundTofé, S., Moreno, J. C., Máiz, L., Alonso, M., Escobar, H., & Barrio, R. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01836 · Cited by 101 · cited 4×
“CF is caused by an autosomal recessive mutation in the CF transmembrane conductance regulator (CFTR) gene, which leads to viscous secretions in multiple organs, especially the lungs [1].”
BackgroundInfluentialPredictors for future cystic fibrosis-related diabetes by oral glucose tolerance test
Schmid, K., Fink, K., Holl, R. W., Hebestreit, H. U., & Ballmann, M. (2013) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2013.06.001 · Cited by 90 · cited 1×
“This is followed by continued decline in insulin secretion, leading to the eventual diagnoses of indeterminant glycemia (INDET), impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) [1, 8, 12, 13].”
BackgroundBizzarri, C., Lucidi, V., Ciampalini, P., Bella, S., Russo, B., & Cappa, M. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03345538 · Cited by 89 · cited 1×
“Some studies have suggested that insulin treatment may be beneficial in dysglycemic states [21, 22].”
BackgroundGodbout, A., Hammana, I., Potvin, S., Mainville, D. J., Räkel, A., Berthiaume, Y., Chiasson, J. L., Coderre, L., & RABASA-LHORET, R. P. R. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.05.010 · Cited by 83 · cited 3×
“Studies thus far have shown poor correlation between HbA1c and CFRD [2, 9, 10, 16, 17].”
BackgroundHbA1c as a screening tool for cystic fibrosis related diabetes
Burgess, J. C., Bridges, N., BANYA, W. A. S., Gyi, K. M., Hodson, M. E., Bilton, D., & Simmonds, N. J. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.03.013 · Cited by 69 · cited 7×
“Furthermore, other possible CF co-morbidities, such as iron deficiency anemia and severe chronic liver disease, may interfere with HbA1c measurements [2].”
BackgroundInfluentialCoriati, A., Ziai, S., Azar, M., Berthiaume, Y., & RABASA-LHORET, R. P. R. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.03.001 · Cited by 46 · cited 1×
“Before the development of frank diabetes, insulin secretion is delayed and blunted, leading to prolonged states of hyperglycemia that may contribute to increased bacterial growth, inflammation and catabolic wasting [1, 7, 15].”
BackgroundHbA1c is not recommended as a screening test for diabetes in cystic fibrosis.
Holl, R. W., Buck, C., Babka, C., Wolf, A. M., & Thon, A. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.126b · Cited by 46 · cited 3×
“Studies thus far have shown poor correlation between HbA1c and CFRD [2, 9, 10, 16, 17].”
BackgroundImpaired Fasting Glucose in Cystic Fibrosis
Frohnert, B. I., Ode, K. L., Moran, A., Nathan, B. M., Laguna, T., Holme, B., & Thomas, W. (2010) · Diabetes Care · doi:10.2337/dc10-0613 · Cited by 40 · cited 1×
“This is followed by continued decline in insulin secretion, leading to the eventual diagnoses of indeterminant glycemia (INDET), impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) [1, 8, 12, 13].”
BackgroundCystic fibrosis-related diabetes: an update on pathophysiology, diagnosis, and treatment
Alves, C., DellaManna, T., & Albuquerque, C. T. M. (2020) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2019-0484 · Cited by 38 · cited 1×
“However, various clinical conditions may promote insulin resistance in CFRD, similar to type II diabetes [4, 5].”
BackgroundCystic fibrosis-related diabetes in adults.
Cawood, T., McKenna, M. J., Gallagher, C. G., Smith, D., Chung, W.-Y., Gibney, J., & O'Shea, D. (2006) · PubMed · Cited by 21
Cited by
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
“Ongoing studies are underway to validate this approach, and A1C is not recommended for screening (133).”
Background2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,433
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s002 · Cited by 2,086
2. Diagnosis and classification of diabetes: standards of care in diabetes-2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s002 · Cited by 1,393
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s002 · Cited by 473
Metadata
- Authors
- Darukhanavala, A., Van Dessel, F., Ho, J., Hansen, M., Kremer, T., & Alfego, D.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Darukhanavala, Amy
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-04-21
- Volume
- 16
- Issue
- 4
- Pages
- e0250036
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC8059836
- OpenAlex
- W3152620040
- Cited by
- 12
- References
- 22
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 4 · 2021: 1
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- cystic fibrosis, HbA1c, cystic fibrosis-related diabetes, impaired fasting glucose, impaired glucose tolerance, diabetes screening, oral glucose tolerance test, pancreatic endocrine dysfunction
- MeSH terms
- Adolescent, Adult, Blood Glucose, Child, Cystic Fibrosis, Diabetes Mellitus, Female, Glucose, Glucose Tolerance Test, Hematologic Tests, Glycated Hemoglobin, Humans, Male, Middle Aged, Prediabetic State, Retrospective Studies, Glucose Intolerance, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.